FDA Gives Approval To Alexion Drug As Treatment For Ultra Rare Genetic Disease The U.S. Food and Drug Administration approved the Alexion drug Kanuma in treatment for a rare genetic disease known as lysosomal acid lipase deficiency (LAL-D). The FDA’s approval marks the first ever enzyme replacement treatment for the disease. by Alyssa Navarro